Continuous Theta Burst Stimulation for Generalized Anxiety Disorder
NCT: NCT07770919 · RECRUITING
Brief Summary
This randomized, rater-blinded clinical trial evaluates the effectiveness, safety, and tolerability of continuous theta burst stimulation (cTBS) in adults with generalized anxiety disorder (GAD). Participants will be randomly assigned in a 1:1 ratio to receive cTBS targeting either the right posterior parietal cortex (R-PPC) or the right dorsolateral prefrontal cortex (R-DLPFC). Participants may be psychotropic-medication naïve or may continue stable psychotropic medication according to the protocol-defined medication stability criteria. The primary objective is to compare changes in anxiety symptom severity, measured using the Hamilton Anxiety Rating Scale (HAM-A), from baseline to the end-of-treatment assessment. Secondary and exploratory assessments include treatment response and remission, quality of life, sleep quality, cognitive function, safety and tolerability, resting electroencephalography (EEG), and transcranial magnetic stimulation combined with EEG (TMS-EEG).
Frequently Asked Questions
What is Continuous Theta Burst Stimulation for Generalized Anxiety Disorder?
Continuous Theta Burst Stimulation for Generalized Anxiety Disorder is a clinical trial registered under NCT07770919. Current status: RECRUITING.
What is the status of NCT07770919?
The current status of NCT07770919 (Continuous Theta Burst Stimulation for Generalized Anxiety Disorder) is: RECRUITING.
When did Continuous Theta Burst Stimulation for Generalized Anxiety Disorder start?
Continuous Theta Burst Stimulation for Generalized Anxiety Disorder started on 2026-09-09.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.